American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

To develop recommendations for prevention and treatment of glucocorticoid‐induced osteoporosis (GIOP).

[1]  X. Ruan,et al.  Chronic Kidney Disease-Mineral and Bone Disorder , 2017, BioMed research international.

[2]  J. Jaremko,et al.  Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  G. Guyatt,et al.  Guideline panels should not GRADE good practice statements. , 2015, Journal of clinical epidemiology.

[4]  I. Petersen,et al.  Monitoring of Patients on Long-Term Glucocorticoid Therapy , 2015, Medicine.

[5]  Ashley L. Pappas,et al.  Effects of maternal bisphosphonate use on fetal and neonatal outcomes. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  Christie M. Bartels,et al.  A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. , 2014, Seminars in arthritis and rheumatism.

[7]  I. Pyrah,et al.  Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. , 2014, Bone.

[8]  D. Branstetter,et al.  Reproductive toxicity of denosumab in cynomolgus monkeys. , 2013, Reproductive toxicology.

[9]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[10]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[11]  D. Moher,et al.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study , 2012, Arthritis care & research.

[12]  B. Clarke,et al.  Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis , 2012 .

[13]  I. Stathopoulos,et al.  The use of bisphosphonates in women prior to or during pregnancy and lactation. , 2011, Hormones.

[14]  JoAnn E. Manson,et al.  The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.

[15]  Tomoaki Tanaka,et al.  Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients. , 2011, Internal medicine.

[16]  J. Kanis,et al.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.

[17]  D. Furst,et al.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.

[18]  C. Ohlsson,et al.  Prevalence and risk factors of vertebral compression fractures in female SLE patients , 2010, Arthritis research & therapy.

[19]  Tomoaki Tanaka,et al.  Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. , 2010, Gender medicine.

[20]  L. Heaney,et al.  The safety of bisphosphonate use in pre-menopausal women on corticosteroids. , 2009, Current drug safety.

[21]  Carl May,et al.  We need minimally disruptive medicine , 2009, BMJ : British Medical Journal.

[22]  J. Griffith,et al.  High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with Systemic Lupus Erythematosus , 2009, The Journal of Rheumatology.

[23]  Tomoaki Tanaka,et al.  Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006. , 2009, Endocrine journal.

[24]  Tomoaki Tanaka,et al.  Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. , 2009, The Journal of clinical endocrinology and metabolism.

[25]  G. Koren,et al.  Pregnancy outcome following in utero exposure to bisphosphonates. , 2009, Bone.

[26]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[27]  G. Koren,et al.  Does treatment with bisphosphonates endanger the human pregnancy? , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[28]  B. Ettinger.  A personal perspective on fracture risk assessment tools. , 2008, Menopause.

[29]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[30]  J. Manson,et al.  Calcium/Vitamin D Supplementation and Cardiovascular Events , 2007, Circulation.

[31]  C. Cooper,et al.  Fracture risk with intermittent high-dose oral glucocorticoid therapy. , 2007, Arthritis and rheumatism.

[32]  A. Ornoy,et al.  The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. , 2006, Reproductive toxicology.

[33]  S. Giannini,et al.  High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. , 2006, Bone.

[34]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[35]  A. Feldstein,et al.  Practice patterns in patients at risk for glucocorticoid-induced osteoporosis , 2005, Osteoporosis International.

[36]  V. Borba,et al.  High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients , 2005, Lupus.

[37]  B. Dijkmans,et al.  Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[38]  H. Hashimoto,et al.  Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. , 2005, The Journal of rheumatology.

[39]  C. Cooper,et al.  A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. , 2005, QJM : monthly journal of the Association of Physicians.

[40]  R. Pazdur,et al.  Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  C. Cooper,et al.  Children and the Risk of Fractures Caused by Oral Corticosteroids , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  J. Katz,et al.  Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. , 2002, Arthritis and rheumatism.

[43]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[44]  M. Hochberg,et al.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis , 2001 .

[45]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  G. Golomb,et al.  Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. , 1999, Teratology.

[47]  N. Lane,et al.  THE SCIENCE AND THERAPY OF BONE LOSS GLUCOCORTICOID-INDUCED , 1998 .

[48]  T. Illidge,et al.  Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[49]  R. G. York,et al.  Intravenous reproductive and developmental toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats and rabbits. , 1995, The Journal of toxicological sciences.

[50]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[51]  P. V. van Riel,et al.  Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis , 1993, Annals of Internal Medicine.

[52]  T. Spector,et al.  The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. , 1993, Arthritis and rheumatism.

[53]  J. Manson,et al.  Effects of the bisphosphonate, alendronate, on parturition in the rat. , 1993, Toxicology and applied pharmacology.

[54]  P. Bentley,et al.  Reproduction toxicity studies with pamidronate. , 1992, Arzneimittel-Forschung.

[55]  C. Fish.  Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk , 1986 .

[56]  Y. Sakiyama,et al.  The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on fetal mice during pregnancy--with emphasis on implantation and fetal weight. , 1986, Journal of Osaka Dental University.

[57]  Sumner J. Yaffe,et al.  Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 8th Edition , 1986 .